Cargando…

Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study

INTRODUCTION: There is currently no validated score capable of classifying cancer-associated pulmonary embolism (PE) in its full spectrum of severity. This study has validated the EPIPHANY Index, a new tool to predict serious complications in cancer patients with suspected or unsuspected PE. METHOD:...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez-Cánovas, Manuel, Jimenez-Fonseca, Paula, Fernández Garay, David, Cejuela Solís, Mónica, Casado Elía, Diego, Coma Salvans, Eva, de la Haba Vacas, Irma, Gómez Sánchez, David, Fernández Montés, Ana, Morales Giménez, Roberto, Biosca Gómez de Tejada, Mercedes, Arrazubi Arrula, Virginia, Sequero López, Silvia, Otero Candelera, Remedios, Sánchez Cendra, Cristina, Justo de la Peña, Marina, Moreno Muñoz, Diana, Orillo Sarmiento, Mayra, Martínez de Castro, Eva, García Escobar, Ignacio, Bernal Vidal, Alejandro, Ortega Moran, Laura, Muñoz Martín, Andrés J., Sánchez Bayona, Rodrigo, Martínez Ortiz, María José, Ayala de la Peña, Francisco, Vicente, Vicente, Carmona-Bayonas, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168567/
https://www.ncbi.nlm.nih.gov/pubmed/37159465
http://dx.doi.org/10.1371/journal.pone.0266305
_version_ 1785038880425115648
author Sánchez-Cánovas, Manuel
Jimenez-Fonseca, Paula
Fernández Garay, David
Cejuela Solís, Mónica
Casado Elía, Diego
Coma Salvans, Eva
de la Haba Vacas, Irma
Gómez Sánchez, David
Fernández Montés, Ana
Morales Giménez, Roberto
Biosca Gómez de Tejada, Mercedes
Arrazubi Arrula, Virginia
Sequero López, Silvia
Otero Candelera, Remedios
Sánchez Cendra, Cristina
Justo de la Peña, Marina
Moreno Muñoz, Diana
Orillo Sarmiento, Mayra
Martínez de Castro, Eva
García Escobar, Ignacio
Bernal Vidal, Alejandro
Ortega Moran, Laura
Muñoz Martín, Andrés J.
Sánchez Bayona, Rodrigo
Martínez Ortiz, María José
Ayala de la Peña, Francisco
Vicente, Vicente
Carmona-Bayonas, Alberto
author_facet Sánchez-Cánovas, Manuel
Jimenez-Fonseca, Paula
Fernández Garay, David
Cejuela Solís, Mónica
Casado Elía, Diego
Coma Salvans, Eva
de la Haba Vacas, Irma
Gómez Sánchez, David
Fernández Montés, Ana
Morales Giménez, Roberto
Biosca Gómez de Tejada, Mercedes
Arrazubi Arrula, Virginia
Sequero López, Silvia
Otero Candelera, Remedios
Sánchez Cendra, Cristina
Justo de la Peña, Marina
Moreno Muñoz, Diana
Orillo Sarmiento, Mayra
Martínez de Castro, Eva
García Escobar, Ignacio
Bernal Vidal, Alejandro
Ortega Moran, Laura
Muñoz Martín, Andrés J.
Sánchez Bayona, Rodrigo
Martínez Ortiz, María José
Ayala de la Peña, Francisco
Vicente, Vicente
Carmona-Bayonas, Alberto
author_sort Sánchez-Cánovas, Manuel
collection PubMed
description INTRODUCTION: There is currently no validated score capable of classifying cancer-associated pulmonary embolism (PE) in its full spectrum of severity. This study has validated the EPIPHANY Index, a new tool to predict serious complications in cancer patients with suspected or unsuspected PE. METHOD: The PERSEO Study prospectively recruited individuals with PE and active cancer or receiving antineoplastic therapy from 22 Spanish hospitals. The estimation of the relative frequency θ of complications based on the EPIPHANY Index categories was made using the Bayesian alternative for the binomial test. RESULTS: A total of 900 patients, who were diagnosed with PE between October 2017 and January 2020, were enrolled. The rate of serious complications at 15 days was 11.8%, 95% highest density interval [HDI], 9.8–14.1%. Of the EPIPHANY low-risk patients, 2.4% (95% HDI, 0.8–4.6%) had serious complications, as did 5.5% (95% HDI, 2.9–8.7%) of the moderate-risk participants and 21.0% (95% HDI, 17.0–24.0%) of those with high-risk episodes. The EPIPHANY Index was associated with overall survival (OS) in patients with different risk levels: median OS was 16.5, 14.4, and 4.4 months for those at low, intermediate, and high risk, respectively. Both the EPIPHANY Index and the Hestia criteria exhibited greater negative predictive value and a lower negative likelihood ratio than the remaining models. The incidence of bleeding at 6 months was 6.2% (95% HDI, 2.9–9.5%) in low/moderate-risk vs 12.7% (95% HDI, 10.1–15.4%) in high-risk (p-value = 0.037) episodes. Of the outpatients, serious complications at 15 days were recorded in 2.1% (95% HDI, 0.7–4.0%) of the cases with EPIPHANY low/intermediate-risk vs 5.3% (95% HDI, 1.7–11.8%) in high-risk cases. CONCLUSION: We have validated the EPIPHANY Index in patients with incidental or symptomatic cancer-related PE. This model can contribute to standardize decision-making in a scenario lacking quality evidence.
format Online
Article
Text
id pubmed-10168567
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-101685672023-05-10 Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study Sánchez-Cánovas, Manuel Jimenez-Fonseca, Paula Fernández Garay, David Cejuela Solís, Mónica Casado Elía, Diego Coma Salvans, Eva de la Haba Vacas, Irma Gómez Sánchez, David Fernández Montés, Ana Morales Giménez, Roberto Biosca Gómez de Tejada, Mercedes Arrazubi Arrula, Virginia Sequero López, Silvia Otero Candelera, Remedios Sánchez Cendra, Cristina Justo de la Peña, Marina Moreno Muñoz, Diana Orillo Sarmiento, Mayra Martínez de Castro, Eva García Escobar, Ignacio Bernal Vidal, Alejandro Ortega Moran, Laura Muñoz Martín, Andrés J. Sánchez Bayona, Rodrigo Martínez Ortiz, María José Ayala de la Peña, Francisco Vicente, Vicente Carmona-Bayonas, Alberto PLoS One Research Article INTRODUCTION: There is currently no validated score capable of classifying cancer-associated pulmonary embolism (PE) in its full spectrum of severity. This study has validated the EPIPHANY Index, a new tool to predict serious complications in cancer patients with suspected or unsuspected PE. METHOD: The PERSEO Study prospectively recruited individuals with PE and active cancer or receiving antineoplastic therapy from 22 Spanish hospitals. The estimation of the relative frequency θ of complications based on the EPIPHANY Index categories was made using the Bayesian alternative for the binomial test. RESULTS: A total of 900 patients, who were diagnosed with PE between October 2017 and January 2020, were enrolled. The rate of serious complications at 15 days was 11.8%, 95% highest density interval [HDI], 9.8–14.1%. Of the EPIPHANY low-risk patients, 2.4% (95% HDI, 0.8–4.6%) had serious complications, as did 5.5% (95% HDI, 2.9–8.7%) of the moderate-risk participants and 21.0% (95% HDI, 17.0–24.0%) of those with high-risk episodes. The EPIPHANY Index was associated with overall survival (OS) in patients with different risk levels: median OS was 16.5, 14.4, and 4.4 months for those at low, intermediate, and high risk, respectively. Both the EPIPHANY Index and the Hestia criteria exhibited greater negative predictive value and a lower negative likelihood ratio than the remaining models. The incidence of bleeding at 6 months was 6.2% (95% HDI, 2.9–9.5%) in low/moderate-risk vs 12.7% (95% HDI, 10.1–15.4%) in high-risk (p-value = 0.037) episodes. Of the outpatients, serious complications at 15 days were recorded in 2.1% (95% HDI, 0.7–4.0%) of the cases with EPIPHANY low/intermediate-risk vs 5.3% (95% HDI, 1.7–11.8%) in high-risk cases. CONCLUSION: We have validated the EPIPHANY Index in patients with incidental or symptomatic cancer-related PE. This model can contribute to standardize decision-making in a scenario lacking quality evidence. Public Library of Science 2023-05-09 /pmc/articles/PMC10168567/ /pubmed/37159465 http://dx.doi.org/10.1371/journal.pone.0266305 Text en © 2023 Sánchez-Cánovas et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Sánchez-Cánovas, Manuel
Jimenez-Fonseca, Paula
Fernández Garay, David
Cejuela Solís, Mónica
Casado Elía, Diego
Coma Salvans, Eva
de la Haba Vacas, Irma
Gómez Sánchez, David
Fernández Montés, Ana
Morales Giménez, Roberto
Biosca Gómez de Tejada, Mercedes
Arrazubi Arrula, Virginia
Sequero López, Silvia
Otero Candelera, Remedios
Sánchez Cendra, Cristina
Justo de la Peña, Marina
Moreno Muñoz, Diana
Orillo Sarmiento, Mayra
Martínez de Castro, Eva
García Escobar, Ignacio
Bernal Vidal, Alejandro
Ortega Moran, Laura
Muñoz Martín, Andrés J.
Sánchez Bayona, Rodrigo
Martínez Ortiz, María José
Ayala de la Peña, Francisco
Vicente, Vicente
Carmona-Bayonas, Alberto
Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study
title Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study
title_full Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study
title_fullStr Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study
title_full_unstemmed Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study
title_short Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study
title_sort prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: validation of the epiphany index in a prospective cohort of patients from the perseo study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168567/
https://www.ncbi.nlm.nih.gov/pubmed/37159465
http://dx.doi.org/10.1371/journal.pone.0266305
work_keys_str_mv AT sanchezcanovasmanuel predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT jimenezfonsecapaula predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT fernandezgaraydavid predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT cejuelasolismonica predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT casadoeliadiego predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT comasalvanseva predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT delahabavacasirma predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT gomezsanchezdavid predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT fernandezmontesana predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT moralesgimenezroberto predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT bioscagomezdetejadamercedes predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT arrazubiarrulavirginia predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT sequerolopezsilvia predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT oterocandeleraremedios predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT sanchezcendracristina predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT justodelapenamarina predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT morenomunozdiana predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT orillosarmientomayra predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT martinezdecastroeva predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT garciaescobarignacio predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT bernalvidalalejandro predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT ortegamoranlaura predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT munozmartinandresj predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT sanchezbayonarodrigo predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT martinezortizmariajose predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT ayaladelapenafrancisco predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT vicentevicente predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy
AT carmonabayonasalberto predictionofseriouscomplicationsinpatientswithpulmonarythromboembolismandsolidcancervalidationoftheepiphanyindexinaprospectivecohortofpatientsfromtheperseostudy